Loss-of-Function CREB3L3 Variants in Patients With Severe Hypertriglyceridemia

Supplemental Digital Content is available in the text. Objective: Genetic determinants of severe hypertriglyceridemia include both common variants with small effects (assessed using polygenic risk scores) plus heterozygous and homozygous rare variants in canonical genes directly affecting triglyceride metabolism. Here, we broadened our scope to detect associations with rare loss-of-function variants in genes affecting noncanonical pathways, including those known to affect triglyceride metabolism indirectly. Approach and Results: From targeted next-generation sequencing of 69 metabolism-related genes in 265 patients of European descent with severe hypertriglyceridemia (≥10 mmol/L or ≥885 mg/dL) and 477 normolipidemic controls, we focused on the association of rare heterozygous loss-of-function variants in individual genes. We observed that compared with controls, severe hypertriglyceridemia patients were 20.2× (95% CI, 1.11–366.1; P=0.03) more likely than controls to carry a rare loss-of-function variant in CREB3L3, which encodes a transcription factor that regulates several target genes with roles in triglyceride metabolism. Conclusions: Our findings indicate that rare variants in a noncanonical gene for triglyceride metabolism, namely CREB3L3, contribute significantly to severe hypertriglyceridemia. Secondary genes and pathways should be considered when evaluating the genetic architecture of this complex trait.

[1]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[2]  I. Minicocci,et al.  Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[3]  John F. Robinson,et al.  Exautomate: A user-friendly tool for region-based rare variant association analysis (RVAA) , 2019, bioRxiv.

[4]  D. Gaudet,et al.  Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia[S] , 2018, Journal of Lipid Research.

[5]  H. Shimano,et al.  CREBH Regulates Systemic Glucose and Lipid Metabolism , 2018, International journal of molecular sciences.

[6]  Ming Zhang,et al.  Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease , 2018, Journal of visualized experiments : JoVE.

[7]  Marcelo P. Segura-Lepe,et al.  Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity , 2017, Nature Genetics.

[8]  John F. Robinson,et al.  Polygenic determinants in extremes of high-density lipoprotein cholesterol[S] , 2017, Journal of Lipid Research.

[9]  R. Hegele,et al.  Genetics of Triglycerides and the Risk of Atherosclerosis , 2017, Current Atherosclerosis Reports.

[10]  Marcelo P. Segura-Lepe,et al.  Rare and low-frequency coding variants alter human adult height , 2016, Nature.

[11]  Ann-Hwee Lee,et al.  Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr−/− Mice , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[12]  C. Jack,et al.  Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease , 2016, BMC Medical Genomics.

[13]  C. Barbagallo,et al.  Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[14]  T. Forte,et al.  Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis , 2015, Journal of biomedical research.

[15]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[16]  R. Hegele,et al.  Chylomicronaemia—current diagnosis and future therapies , 2015, Nature Reviews Endocrinology.

[17]  Alison B Kohan,et al.  Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease , 2015, Current opinion in endocrinology, diabetes, and obesity.

[18]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[19]  G. Lettre,et al.  Rare variant association studies: considerations, challenges and opportunities , 2015, Genome Medicine.

[20]  C. Bunker,et al.  Resequencing of LPL in African Blacks and associations with lipoprotein–lipid levels , 2015, European Journal of Human Genetics.

[21]  J. Borén,et al.  The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. , 2014, The lancet. Diabetes & endocrinology.

[22]  G. Abecasis,et al.  Rare-variant association analysis: study designs and statistical tests. , 2014, American journal of human genetics.

[23]  J. Borén,et al.  Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing , 2014, Journal of internal medicine.

[24]  Ann-Hwee Lee,et al.  Transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH[S] , 2014, Journal of Lipid Research.

[25]  John F. Robinson,et al.  LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias , 2014, Journal of Lipid Research.

[26]  J. Spence Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2013 .

[27]  N. Laird,et al.  Statistical Challenges in Sequence-Based Association Studies with Population- and Family-Based Designs , 2013 .

[28]  Xihong Lin,et al.  Optimal tests for rare variant effects in sequencing association studies. , 2012, Biostatistics.

[29]  M. Rieder,et al.  Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. , 2012, American journal of human genetics.

[30]  J. Graaf,et al.  Serum triglycerides and risk of cardiovascular disease. , 2012, Biochimica et biophysica acta.

[31]  E. Parks,et al.  Postprandial metabolism of meal triglyceride in humans. , 2012, Biochimica et biophysica acta.

[32]  R. Hegele,et al.  The Complex Genetic Basis of Plasma Triglycerides , 2012, Current Atherosclerosis Reports.

[33]  S. Yusuf,et al.  Excess of Rare Variants in Non–Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia , 2012, Circulation. Cardiovascular genetics.

[34]  R. Hegele,et al.  The transcription factor cyclic AMP–responsive element–binding protein H regulates triglyceride metabolism , 2011, Nature Medicine.

[35]  S. Kathiresan,et al.  Genetic determinants of plasma triglycerides , 2011, Journal of Lipid Research.

[36]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[37]  L. Havekes,et al.  The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? , 2004, Current opinion in lipidology.

[38]  Hao Li,et al.  Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. , 1994, The Journal of biological chemistry.

[39]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[40]  I. Goldberg,et al.  Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.

[41]  S B Hulley,et al.  Distribution of triglyceride and total, LDL and HDL cholesterol in several populations: a cooperative lipoprotein phenotyping study. , 1977, Journal of chronic diseases.

[42]  R. Hegele,et al.  Severe hypertriglyceridemia is primarily polygenic. , 2019, Journal of clinical lipidology.

[43]  K. Michailidou Meta-Analysis of Common and Rare Variants. , 2018, Methods in molecular biology.

[44]  M. Spector,et al.  Human apolipoprotein A-IV: displacement from the surface of triglyceride-rich particles by HDL2-associated C-apoproteins. , 1985, Journal of lipid research.